Frank Dieterle

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi Monitoring kidney safety in drug development: emerging technologies and their implications
    Frank Dieterle
    Novartis Pharma AG, Klybeckstrasse 141, CH 4057 Basel, Switzerland
    Curr Opin Drug Discov Devel 11:60-71. 2008
  2. ncbi Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury
    Frank Dieterle
    Novartis Institutes for BioMedical Research, Novartis, Basel, Switzerland
    Nat Biotechnol 28:463-9. 2010
  3. ncbi Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
    Frank Dieterle
    Novartis Pharma AG, Basel, Switzerland
    Nat Biotechnol 28:455-62. 2010
  4. ncbi New technologies around biomarkers and their interplay with drug development
    Frank Dieterle
    Novartis Pharma AG, Development, 4002, Basel, Switzerland
    Anal Bioanal Chem 390:141-54. 2008
  5. ncbi Impact of biomarker development on drug safety assessment
    Estelle Marrer
    Translational Sciences, Novartis Institutes for BioMedical Research, CH 4002 Basel, Switzerland
    Toxicol Appl Pharmacol 243:167-79. 2010
  6. ncbi Promises of biomarkers in drug development--a reality check
    Estelle Marrer
    Novartis Pharma AG, Development, 4002 Basel, Switzerland
    Chem Biol Drug Des 69:381-94. 2007
  7. ncbi Biomarkers in oncology drug development: rescuers or troublemakers?
    Estelle Marrer
    Novartis Institutes for BioMedical Research, Translational Sciences, Novartis, Klybeckstr 141, CH 4002 Basel, Switzerland
    Expert Opin Drug Metab Toxicol 4:1391-402. 2008
  8. ncbi Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring
    Patrick Y Muller
    Novartis Institutes for BioMedical Research, Basel, Switzerland
    Expert Opin Drug Metab Toxicol 5:1023-38. 2009
  9. ncbi Application of metabonomics in a comparative profiling study reveals N-acetylfelinine excretion as a biomarker for inhibition of the farnesyl pathway by bisphosphonates
    Frank Dieterle
    Pharmaceuticals Division, F Hoffman La Roche Ltd, 4070 Basel, Switzerland
    Chem Res Toxicol 20:1291-9. 2007
  10. ncbi Application of metabonomics in a compound ranking study in early drug development revealing drug-induced excretion of choline into urine
    Frank Dieterle
    F. Hoffmann-La Roche Ltd, Pharmaceuticals Division, PRBD-E, Building 065/512, 4070-Basel, Switzerland
    Chem Res Toxicol 19:1175-81. 2006

Detail Information

Publications12

  1. ncbi Monitoring kidney safety in drug development: emerging technologies and their implications
    Frank Dieterle
    Novartis Pharma AG, Klybeckstrasse 141, CH 4057 Basel, Switzerland
    Curr Opin Drug Discov Devel 11:60-71. 2008
    ..Finally, the associated regulatory processes for use in clinics are also discussed...
  2. ncbi Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury
    Frank Dieterle
    Novartis Institutes for BioMedical Research, Novartis, Basel, Switzerland
    Nat Biotechnol 28:463-9. 2010
    ..The recognition of the qualification of these biomarkers by the EMEA and FDA will significantly enhance renal safety monitoring...
  3. ncbi Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
    Frank Dieterle
    Novartis Pharma AG, Basel, Switzerland
    Nat Biotechnol 28:455-62. 2010
    ....
  4. ncbi New technologies around biomarkers and their interplay with drug development
    Frank Dieterle
    Novartis Pharma AG, Development, 4002, Basel, Switzerland
    Anal Bioanal Chem 390:141-54. 2008
    ..The roles as well as the pros and cons of different disciplines such as genetics, genomics, proteomics, metabonomics, and assay development will be discussed...
  5. ncbi Impact of biomarker development on drug safety assessment
    Estelle Marrer
    Translational Sciences, Novartis Institutes for BioMedical Research, CH 4002 Basel, Switzerland
    Toxicol Appl Pharmacol 243:167-79. 2010
    ..A last part will be dedicated to safety biomarker development in general, from identification to diagnostic tests, using the kidney safety biomarkers success as an illustrative example...
  6. ncbi Promises of biomarkers in drug development--a reality check
    Estelle Marrer
    Novartis Pharma AG, Development, 4002 Basel, Switzerland
    Chem Biol Drug Des 69:381-94. 2007
    ..Besides discussing their perspectives of applications, the present article also illustrates the future of biomarker development in terms of qualification for regulatory use and co-development...
  7. ncbi Biomarkers in oncology drug development: rescuers or troublemakers?
    Estelle Marrer
    Novartis Institutes for BioMedical Research, Translational Sciences, Novartis, Klybeckstr 141, CH 4002 Basel, Switzerland
    Expert Opin Drug Metab Toxicol 4:1391-402. 2008
    ....
  8. ncbi Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring
    Patrick Y Muller
    Novartis Institutes for BioMedical Research, Basel, Switzerland
    Expert Opin Drug Metab Toxicol 5:1023-38. 2009
    ..In addition, the current regulatory status is presented and discussed in view of recent changes in regulatory acceptance by health authorities...
  9. ncbi Application of metabonomics in a comparative profiling study reveals N-acetylfelinine excretion as a biomarker for inhibition of the farnesyl pathway by bisphosphonates
    Frank Dieterle
    Pharmaceuticals Division, F Hoffman La Roche Ltd, 4070 Basel, Switzerland
    Chem Res Toxicol 20:1291-9. 2007
    ..This is the reported mode of action of bisphosphonates. Until now, N-acetylfelinine was exclusively observed in the urine of felidae species, where it is believed to be a precursor to a pheromone...
  10. ncbi Application of metabonomics in a compound ranking study in early drug development revealing drug-induced excretion of choline into urine
    Frank Dieterle
    F. Hoffmann-La Roche Ltd, Pharmaceuticals Division, PRBD-E, Building 065/512, 4070-Basel, Switzerland
    Chem Res Toxicol 19:1175-81. 2006
    ....
  11. ncbi Urinary nucleosides as potential tumor markers evaluated by learning vector quantization
    Frank Dieterle
    Institute of Physical and Theoretical Chemistry, Auf der Morgenstelle 8, D 72076 Tubingen, Germany
    Artif Intell Med 28:265-79. 2003
    ..As at least some of these features play an important role in an implementation into a medical decision support system, it is recommended to use LVQ for an extended study...